MENU
+Compare
LYRA
Stock ticker: NASDAQ
AS OF
May 8 closing price
Price
$0.09
Change
-$0.01 (-10.00%)
Capitalization
6.26M

LYRA Lyra Therapeutics Forecast, Technical & Fundamental Analysis

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients... Show more

LYRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for LYRA with price predictions
May 08, 2025

LYRA's RSI Indicator recovers from oversold territory

The RSI Oscillator for LYRA moved out of oversold territory on April 22, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In of the 33 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Moving Average Convergence Divergence (MACD) for LYRA just turned positive on April 22, 2025. Looking at past instances where LYRA's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where LYRA advanced for three days, in of 238 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on May 08, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on LYRA as a result. In of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LYRA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

LYRA broke above its upper Bollinger Band on April 29, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for LYRA entered a downward trend on April 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.580) is normal, around the industry mean (14.243). P/E Ratio (0.000) is within average values for comparable stocks, (62.770). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.866). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (4.329) is also within normal values, averaging (253.449).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. LYRA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LYRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
LYRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

LYRA is expected to report earnings to fall 19.23% to -10 cents per share on August 12

Lyra Therapeutics LYRA Stock Earnings Reports
Q2'25
Est.
$-0.10
Q1'25
Missed
by $0.01
Q4'24
Beat
by $0.03
Q3'24
Beat
by $0.04
Q2'24
Missed
by $0.41
The last earnings report on May 06 showed earnings per share of -12 cents, missing the estimate of -11 cents. With 3.38M shares outstanding, the current market capitalization sits at 6.26M.
A.I. Advisor
published General Information

General Information

a clinical-stage therapeutics company, which develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
480 Arsenal Way
Phone
+1 617 393-4600
Employees
145
Web
https://lyratherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
XAGE0.160.01
+7.56%
Longevity Health Holdings Inc
MITK8.810.35
+4.14%
Mitek Systems
DXC15.860.40
+2.59%
DXC Technology Company
FLEX38.520.57
+1.50%
Flex Ltd
TNGX1.10-0.05
-4.35%
Tango Therapeutics

LYRA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, LYRA has been closely correlated with GLYC. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if LYRA jumps, then GLYC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LYRA
1D Price
Change %
LYRA100%
-10.10%
GLYC - LYRA
75%
Closely correlated
+0.37%
EYPT - LYRA
57%
Loosely correlated
+0.16%
SQZB - LYRA
29%
Poorly correlated
N/A
BCYC - LYRA
27%
Poorly correlated
+5.14%
ARVN - LYRA
26%
Poorly correlated
+2.10%
More

Groups containing LYRA

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LYRA
1D Price
Change %
LYRA100%
-10.10%
LYRA
(2 stocks)
92%
Closely correlated
-4.86%